New Wegovy® Pill vs. Wegovy® Injection: What’s the Difference?
The FDA-Approved Oral GLP-1 Wegovy® Weight Loss Pill is Now Available in New Jersey
The Wegovy® Pill for weight loss is now available throughout New Jersey after receiving FDA approval on December 22, 2025. For patients who have avoided weight loss injections due to needle-anxiety or those managing weekly injections this once-daily GLP-1 pill offers a needle-free alternative.
This comprehensive guide to the Wegovy® Pill reviews the clinical evidence, practical differences, and key factors to help you make an informed decision and have a meaningful discussion with your doctor about which option is right for you.
Key Takeaways:
- The FDA approved the first oral GLP-1 pill for weight loss (Wegovy® pill, 25 mg) on December 22, 2025.
- Weight loss on the Wegovy® Pill is comparable between the pill and the injection. Average weight loss is 13.6% with the daily Wegovy® pill vs. 14.9% with weekly Wegovy® injections based on clinical trials
- The major difference between the Wegovy® pill and injection is timing of the doses. The pill requires daily morning dose on empty stomach with 30-minute wait; injection is once weekly anytime
- The Wegovy® pill is more affordable than the injection. It is $149-349/month for the Wegovy® pill vs. $349month for injections (without insurance)
- Choose the pill if you have needle anxiety or travel frequently; stick with injections if achieving good results or have unpredictable mornings.
- Always consult your NJBC weight loss doctor to determine which Wegovy® formulation is right for your weight loss journey
Clinical Evidence: Comparing the Effectiveness of the Wegovy® Pill vs Injection
Both the Wegovy® pill and injection deliver similar weight loss results in clinical trials.
In studies, patients taking the Wegovy® pill (25 mg daily, the highest dose) lost an average of 13.6% of their body weight over 64 weeks when combined with diet and exercise. Patients taking the Wegovy® injection (2.4 mg weekly) lost an average of 14.9% over 68 weeks.
Bottom line: Both formulations produce comparable, clinically meaningful weight loss—around 13-15% on average. Individual results will vary based on adherence to diet and exercise recommendations.
Wegovy® Injections and Pills: How They Work
Both formulations contain semaglutide and work by mimicking gut hormones to suppress appetite. The pill requires a much higher dose (25 mg daily vs. 2.4 mg weekly injection) because less than 1% is absorbed through the digestive system, even with the special absorption enhancer it contains – which is why it’s important to take the pill exactly as directed to see the full benefits.
Key Differences: Wegovy® Injection vs Wegovy® Pill
| Feature | Wegovy® Injection | Wegovy® Pill |
| Frequency | Once weekly | Once daily |
| Timing | Anytime, with or without food | Empty stomach AM; wait 30 min before eating/drinking |
| Storage | Refrigeration required | Room temperature |
| Cost (without insurance) | $349/month | $149-$349/month |
| Side Effects | Nausea, diarrhea, abdominal pain & fatigue | Nausea, diarrhea, abdominal pain & fatigue |
What is Wegovy®?
Wegovy® (semaglutide) is an FDA-approved medication for chronic weight management in adults with obesity or are overweight who also have weight-related medical conditions. It works by mimicking a natural gut hormone called GLP-1, which helps regulate appetite and food intake. Wegovy® reduces hunger and helps you feel fuller faster and longer, making it easier to maintain a reduced-calorie diet.
Until recently, Wegovy® was only available as a once-weekly injection. Now, with the approval of the oral version, patients have two delivery options—both containing the same active ingredient, semaglutide, but offering different administration methods and lifestyle considerations.
Which Wegovy® Formulation Is Right for You? Key Considerations
At New Jersey Bariatric Center's six locations across NJ, our weight loss doctors can help you determine which option is right for you. If you're already using Wegovy® injections successfully, you may wonder if switching to the pill makes sense. The good news is you don't need to switch unless the pill better fits your lifestyle. Here is some information to consider
The injection may work best if you:
- Are achieving good results with minimal side effects
- Prefer weekly dosing over daily medication
- Have unpredictable morning schedules
- Take multiple morning medications that would need rescheduling
Consider the pill if you:
- Have needle anxiety or injection site reactions
- Can commit to a strict morning routine (empty stomach, 30-minute wait)
- Travel frequently and need medication without refrigeration
- Want potentially lower out-of-pocket costs
Remember: You don't need to switch if your current treatment is working well. Both formulations are effective based on clinical trial data. The best choice is the one that fits your life.
The Bottom Line
The Wegovy® pill delivers comparable weight loss to injections at the highest dose, however it requires daily dosing with timing guidelines. The pill is ideal for patients with needle aversion or frequent travelers, as refrigeration is not required. However, the morning routine restrictions may not suit everyone.
RELATED: Traveling with Weight Loss Medication like Wegovy®® & Zepbound®?
The most effective medication is the one you'll take consistently. Talk with your NJBC weight loss doctor to determine which formulation fits your lifestyle, medical needs, and treatment goals.
Important: This article is for informational purposes only. Always consult with your doctor before starting or changing weight loss medications.
Yes, clinical trials show comparable weight loss between the two formulations. The OASIS 4 trial found that patients taking the oral Wegovy® pill lost an average of 13.6% of their body weight over 64 weeks, while the STEP 1 trial for injectable Wegovy® showed 14.9% weight loss over 68 weeks. Both formulations contain the same active ingredient (semaglutide) and work by the same mechanism—suppressing appetite through GLP-1 receptor activation. The slight difference in results is not clinically significant, and individual results vary based on adherence to diet and exercise recommendations.
Without insurance, the Wegovy® pill is generally more affordable. The starting dose (1.5 mg) costs approximately $149 per month, with the maintenance dose (25 mg) ranging from $149-349 monthly. Injectable Wegovy® costs $349 per month depending on the dose, though Novo Nordisk is offering promotional pricing of $199 for the first two months through March 2026.
Important: Insurance coverage varies significantly. Many plans have established coverage for injectable Wegovy® but may not yet cover the pill formulation, as it was only approved in December 2025. With insurance, copays for either form could be as low as $25 or completely covered, depending on your specific plan. Always verify coverage with your insurance provider.
The Wegovy® pill must be taken on an empty stomach first thing in the morning with a maximum of 4 ounces of water. You must then wait at least 30 minutes before eating, drinking anything other than water, or taking any other oral medications. This strict timing is essential because the pill contains an absorption enhancer that needs specific conditions to work properly.
The pill must be swallowed whole and cannot be split, crushed, chewed, or dissolved. If you typically take other medications in the morning, insulin, or medications that must be taken with food, you'll need to delay them by at least 30 minutes. The injectable Wegovy®, in contrast, can be taken at any time of day with or without food, offering much more flexibility.
Sources:
- OASIS 4 trial (NEJM 2025), FDA approval documentation (Dec 2025), Wegovy® prescribing information (Novo Nordisk 2025).
- Wegovy®® Side Effects | Wegovy®® (semaglutide) Injection 2.4 mg. www.Wegovy®.com. https://www.Wegovy®.com/taking-Wegovy®/side-effects.html
- Wilding JPH, Batterham RL, Calanna S. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021;384(11):989-1002. doi:https://doi.org/10.1056/NEJMoa2032183
